Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 176 to 200 of 410

Guidance and quality standards awaiting development
Title	Type
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]	Technology appraisal guidance
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]	Technology appraisal guidance
Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression	Technology appraisal guidance
KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication	HealthTech guidance
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]	Technology appraisal guidance
Laroprovstat for treating primary hypercholesterolaemia or mixed dyslipidaemia disease	Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]	Technology appraisal guidance
Lemborexan for treating insomnia [GID-TA12011]	Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]	Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]	Technology appraisal guidance
Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]	Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]	Technology appraisal guidance
Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [GID-TA12013]	Technology appraisal guidance
Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Luspatercept for treating haemoglobin H disease [ID6714]	Technology appraisal guidance
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]	Technology appraisal guidance
Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over	Technology appraisal guidance
Managing symptoms with an uncertain cause	Quality standard
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance

Results per page

10
25
50
All